The Supreme Court has allowed Natco Pharma to launch its generic version of the spinal muscular atrophy drug Risdiplam in India, dismissing...

F. Hoffmann-La Roche AG has approached the Supreme Court. This follows a Delhi High Court decision permitting Natco Pharma to introduce a g...

The Delhi High Court has permitted Natco Pharma to launch its affordable generic version of risdiplam, a crucial drug for spinal muscular a...

Recent GST rate cuts on critical medicines are set to significantly reduce costs for treatments of conditions like multiple myeloma, lung c...

A recent report in The Times of India reveals that Roche may have profited immensely from risdiplam, a drug for spinal muscular atrophy (SM...

The Supreme Court is set to examine a plea alleging that Samay Raina, host of "India's Got Latent," ridiculed disabled individuals. The cou...

Ahead of Budget 2025, experts and industry leaders propose measures to address the $530 billion credit gap facing the MSME sector.

Karnataka launched free treatment for Spinal Muscular Atrophy (SMA) at the Indira Gandhi Institute of Child Health in Bengaluru. The initia...

Budget 2024: Finance Minister Nirmala Sitharaman presented the Budget for 2024-25, marking her 7th consecutive presentation. This budget is...

The high cost of Zolgensma, a one-time gene therapy used to treat spinal muscular atrophy (SMA) in children under two, is to limited patien...

Since its launch, over 4,000 SMA patients across over 50 countries have benefitted from the drug, Roche said in a statement.

Justice P B Suresh Kumar said the court does not want to interdict the crowdfunding process, but it wants the funds to go to the government...

Raising the issue through a zero-hour mention, Jharna Das Baidya said subsidised and non-subsidised LPG prices were raised by a steep Rs 12...